Should a pre-IPO medtech company hire a fractional Chief Revenue Officer in 2027?
Direct Answer
A fractional CRO brings the same strategic muscle as a full-time CRO but with flexible commitment and lower total cost. For a medtech company preparing for IPO, the key advantage is speed: you can install a proven revenue leader in weeks, not months, without the search fees, relocation, or equity grant that a permanent hire demands. The trade-off is that a fractional executive will not be in your office every day, and you must be deliberate about knowledge transfer and decision-making cadence. If your board is pushing for predictable revenue operations and a credible growth narrative for the S-1, a fractional CRO can deliver that without blowing your G&A budget.
Why pre-IPO medtech is a unique fit for fractional revenue leadership
Medtech companies face a specific set of challenges that make fractional CROs particularly valuable. Your sales cycles often stretch 9–18 months, involve clinical and economic buyers, and require navigating hospital system procurement, group purchasing organizations (GPOs), and regulatory timelines. A generalist CRO from a SaaS background will not understand the nuance of capital equipment vs. consumable revenue models, or how to price a device against an existing standard of care.
A fractional CRO with medtech experience can walk in and immediately help you build a revenue model that investors will trust. They know how to structure a sales compensation plan that rewards long-cycle deal progression, not just closed-won revenue. They understand that your pipeline is measured in months, not weeks, and that your board will want to see leading indicators like "accounts in active evaluation" rather than just trailing bookings.
What a fractional CRO actually does for a pre-IPO medtech company
The work is not theoretical. In your first 30 days, a fractional CRO should:
- Audit your current revenue operations: CRM hygiene (Salesforce or HubSpot), forecast accuracy, and deal review cadence.
- Build a board-ready revenue dashboard that shows pipeline coverage, win rates by segment, and cohort retention.
- Align your pricing and packaging with the IPO narrative: are you selling a "platform" or a "product"? The answer changes your multiple.
- Coach your VP of Sales on how to run a weekly forecast that the board trusts.
- Design a channel strategy if you are selling through distributors or med-surg reps.
After 90 days, the focus shifts to execution: attending key deal reviews, helping close strategic accounts, and preparing the revenue section of your S-1 draft. A good fractional CRO will also mentor your internal team so that when you do hire a permanent CRO, the transition is smooth.
When a fractional CRO is the wrong answer
There are three scenarios where you should not hire a fractional CRO:
- Your company is pre-revenue or below $2M ARR. At that stage, you need a founder-led sales motion, not a part-time executive. A fractional CRO cannot replace the founder's passion and product knowledge in early customer conversations.
- Your internal team is too junior. If your VP of Sales has never managed a team of more than three reps, and your ops person is an admin with a Salesforce login, a fractional CRO will be a solo operator with no one to delegate to. The model fails.
- You need a cultural transformation. If your sales team is demoralized, your comp plan is broken, and your pipeline is empty, you need a full-time leader who eats lunch with the team every day. A fractional CRO can advise on the transformation but cannot live it.
How to find and evaluate a fractional CRO for medtech
- Direct medtech experience. Ask: "Have you sold to hospital systems, GPOs, or surgical centers?" If they say "I sold SaaS to healthcare," that is not the same thing.
- IPO preparation experience. Ask: "Have you built a revenue model for an S-1? Do you know what underwriting bankers look for in pipeline coverage ratios?"
- References from similar-stage companies. Call their past clients and ask: "Did they actually improve forecast accuracy? Did they help close deals, or just talk about frameworks?"
Do not hire a fractional CRO who cannot name the specific medtech sales motions they have led. The best candidates will have held full-time CRO or VP Sales roles at medtech companies before going fractional.
The cost breakdown and what to negotiate
A fractional CRO for a pre-IPO medtech company will typically charge $15,000 to $40,000 per month for 8 to 12 days of engagement. The range depends on:
- Scope of work: Pure strategy (pricing, segmentation, board prep) is at the lower end. Hands-on pipeline management and team coaching is at the higher end.
- Days per month: Most engagements are 8–12 days. More days cost more.
- Stage of company: A $10M ARR company pays less than a $40M ARR company because the complexity and stakes are lower.
- Equity: Most fractional CROs will accept a small equity grant (0.1%–0.5%) in lieu of higher cash, but they will not take a full CRO-sized grant.
You can negotiate a month-to-month contract with a 60-day notice period. Avoid long-term lockups. The engagement should have clear milestones: "By month three, we will have a board-ready dashboard, a revised comp plan, and a pipeline coverage ratio above 3x."
FAQ
What is the minimum ARR for a fractional CRO to make sense? $10M ARR is a reasonable floor. Below that, the founder should still be the primary revenue driver. Above $50M ARR, you likely need a full-time CRO to manage the complexity and culture.
How many days per week will a fractional CRO actually work? Most fractional CROs commit to 8–12 days per month, which translates to roughly 2–3 days per week. They will be available for urgent calls and board meetings outside those days, but you should not expect daily presence.
Can a fractional CRO help with the IPO roadshow? Yes, if they have IPO experience. They can prepare the revenue section of the S-1, build the financial model for the roadshow, and coach you on how to answer investor questions about pipeline and churn. They will not be on the roadshow itself — that is the CEO and CFO's role.
Will a fractional CRO replace my VP of Sales? No. A fractional CRO is a strategic partner to the VP of Sales, not a replacement. If your VP of Sales is weak, you should replace them before bringing in a fractional CRO. If your VP of Sales is strong but lacks strategic experience, a fractional CRO can mentor them.
How do I measure the success of a fractional CRO? Set three clear metrics at the start: (1) forecast accuracy improves to within 10% of actuals, (2) pipeline coverage ratio reaches 3x or higher, and (3) the board approves the revenue section of the S-1 draft. If those are not met within 90 days, the engagement is not working.
What happens when I need a full-time CRO later? A good fractional CRO will help you write the job description, interview candidates, and manage the transition. Some fractional CROs will even stay on for a 30–60 day overlap with the new hire to ensure continuity.
Sources
- Pavilion — Community for revenue leaders with fractional and full-time roles
- RevOps Co-op — Revenue operations community with resources on fractional leadership
- Harvard Business Review — General management and leadership frameworks
- First Round Review — Practical advice for startup executives
- SaaStr — Revenue leadership and go-to-market insights
- LinkedIn — Network for finding and vetting fractional CRO candidates
People also search for: fractional chief revenue officer · hire a fractional chief revenue officer · fractional chief revenue officer near me · fractional chief revenue officer cost